Pancreatic cancer is an aggressive neoplasia and has a fatal prognosis, with approximately 85% of patients diagnosed in advanced stages of the disease. The purpose of this study was to determine if the loss of e-cadherin expression in pancreatic pancreatic is a predictor of the prognosis of this disease. This research is based on a retrospective study performed on a group of 81 patients who benefited from pancreatic resection in our Surgical Clinic, between January 2008 and December 2016 and assessing the positivity of e-cadherin. There were no correlations between e-cadherin expression and other clinic-pathological factors, including gender, age, tumor status, lymph node metastasis, microscopic vascular invasion, perineural invasion. Low-differentiated pancreatic cancer was more likely to exhibit e-cadherin expression loss than well-differentiated forms of cancer (p-0.07). The mean survival in e-cadherin positive patients (17.1 months) was significantly worse compared to those with E-cadherin absent (6.8 months).In conclusion, we found that partial loss of e-cadherin in primary pancreatic adenocarcinomas is an independent predictor of a negative outcome among patients with curative surgical resection of pancreatic lesions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.